New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
An L-shaped Relationship Between Dietary Vitamin K and Atherosclerotic Cardiovascular Disease
Few studies link vitamin K intake with incident atherosclerotic cardiovascular disease (ASCVD), and the specific mechanism remains uncertain. We aimed to evaluate the relationship between dietary vitamin K and ASCVD. (Source: Clinical Nutrition ESPEN)
Source: Clinical Nutrition ESPEN - April 19, 2024 Category: Nutrition Authors: Yue Wu, Hong-Ju Xiang, Min Yuan Source Type: research
A Rare Cause of Coagulopathy in the Emergency Department: Cefoperazone Use
Cefoperazone (CPZ) is an antibiotic widely used for moderate to severe infections, especially in countries where resources are difficult to access. This case report aimed to draw attention to coagulopathy, a potential side effect of CPZ. This side effect can cause high mortality and morbidity in patients. In the mechanism of CPZ causing coagulopathy, it is reported that effects such as binding to vitamin K, disrupting vitamin K metabolism, and preventing platelet aggregation are responsible. In this presentation, a case who came to the emergency department with the complaint of hematuria caused by coagulopathy after the us...
Source: Journal of Emergency Nursing: JEN - April 18, 2024 Category: Nursing Authors: Metin Ocak, Hatice Y ıldız, Metin Yadigaroğlu, Murat Yücel, Murat Güzel Tags: Case Review Source Type: research
Testing for the lupus anticoagulant: the good, the bad, and the ugly
Res Pract Thromb Haemost. 2024 Mar 18;8(3):102385. doi: 10.1016/j.rpth.2024.102385. eCollection 2024 Mar.ABSTRACTLupus anticoagulant (LA) represents 1 of the laboratory criteria for classification of patients as having definite antiphospholipid syndrome (APS). The other 2 laboratory criteria are anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies. At least 1 of these antiphospholipid antibody (aPL) tests need to be positive, with evidence of persistence, together with evidence of at least 1 clinical criterion for APS, before a patient can be classified as having definite APS. LA and other aPL assays are als...
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Emmanuel J Favaloro Leonardo Pasalic Rita Selby Source Type: research
Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper
Thromb Haemost. 2024 Apr 16. doi: 10.1055/s-0044-1782688. Online ahead of print.ABSTRACTIn the era of direct oral anticoagulants, vitamin K antagonists retain a clinically relevant role in thrombotic disorders. In Italy, approximately 20% of the patients on anticoagulant therapies receives a VKA, in most cases warfarin. The optimal management of this drug is challenging and cannot disregard its intricate and unpredictable pharmacokinetic properties and patient's thrombotic and bleeding risk. Several clinical issues encountered during warfarin treatment are still unanswered and are tentatively addressed by physicians. In th...
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Silvia Galliazzo Paolo Bucciarelli Doris Barcellona Antonio Ciampa Elvira Grandone Giuseppe Malcangi Giuseppe Rescigno Alessandro Squizzato Vincenzo Toschi Sophie Testa Daniela Poli Source Type: research
Testing for the lupus anticoagulant: the good, the bad, and the ugly
Res Pract Thromb Haemost. 2024 Mar 18;8(3):102385. doi: 10.1016/j.rpth.2024.102385. eCollection 2024 Mar.ABSTRACTLupus anticoagulant (LA) represents 1 of the laboratory criteria for classification of patients as having definite antiphospholipid syndrome (APS). The other 2 laboratory criteria are anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies. At least 1 of these antiphospholipid antibody (aPL) tests need to be positive, with evidence of persistence, together with evidence of at least 1 clinical criterion for APS, before a patient can be classified as having definite APS. LA and other aPL assays are als...
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Emmanuel J Favaloro Leonardo Pasalic Rita Selby Source Type: research
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study
ConclusionsThe serum level of PIVKA-II was significantly higher in children with hepatic tumors, especially those with malignant tumors. The combination of PIVKA-II with AFP further increased the diagnostic performance.Trial registrationClinical Trials, NCT03645655. Registered 20 August 2018,https://www.clinicaltrials.gov/ct2/show/NCT03645655. (Source: Hepatology International)
Source: Hepatology International - April 16, 2024 Category: Infectious Diseases Source Type: research
Factor XI: structure, function and therapeutic inhibition
AbstractArterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as ...
Source: Journal of Thrombosis and Thrombolysis - April 16, 2024 Category: Hematology Source Type: research
Late Onset Vitamin K Deficiency Bleeding in a Neonate and Role of Elevated PIVKA-II Levels
(Source: Indian Journal of Pediatrics)
Source: Indian Journal of Pediatrics - April 16, 2024 Category: Pediatrics Source Type: research
On the relationship between various anticoagulants and robot-assisted radical prostatectomy: a single-surgeon serial analysis
This study aims to explore the safety of robot-assisted prostatectomy in anticoagulated patients, without any exclusion criteria. The study included 500 patients who underwent RARP by a single surgeon between April 2019 and August 2022. Patients were divided into two groups: Group 1, consisting of 376 men (75.2%), did not receive any anticoagulation, while Group 2, with 124 patients (24.8%), received different forms of anticoagulation. Then, the anticoagulation group was divided into 4 subgroups according to their definite anticoagulation: the aspirin 15.6%, new oral anticoagulants (NOAC) 5.4%, Vitamin K antagonist (VKA) 2...
Source: Journal of Robotic Surgery - April 13, 2024 Category: Surgery Source Type: research
Validating nutrient selection for product-group-specific nutrient indices for use as functional units in life cycle assessment of foods
Br J Nutr. 2024 Apr 12:1-23. doi: 10.1017/S0007114524000709. Online ahead of print.ABSTRACTThe ability to provide adequate nutrition is considered a key factor in evaluating the sustainability of foods and diets. Nutrient indices are used as functional units (FUs) in life cycle assessment of foods to include nutritional performance in the environmental assessment of a product. Several general and food group-specific nutrient indices exist but many lack validation, particularly when used as FU. In addition, the nutrient selection strategies and reference units for nutrient intake can vary considerably among studies. To vali...
Source: The British Journal of Nutrition - April 12, 2024 Category: Nutrition Authors: Anna K årlund Venla Kytt ä Tiina Pellinen Hanna L Tuomisto Anne-Maria Pajari Marjukka Kolehmainen Merja Saarinen Source Type: research
